AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00490490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (XRT)
Description: Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
Study NCT00490490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide (KI)
Description: Potassium iodide (KI) will be administered as:~* Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~* Lugol's solution 20 drops orally 3-times-a-day, OR~* KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab
Study NCT04101318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Conformité Européene marked product
Description: New Baseplate is not named at this point
Study NCT04101318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conformité Européene marked competitor products
Description: The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.
Study NCT03482466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
Study NCT02022904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared (NIR) emissive nanotechnology
Study NCT00162448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-394136
Description: Oral Solution, Oral, 100 mg, Single dose, 1 day.
Study NCT00162448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single dose, 1 day.
Study NCT00288184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
Study NCT00288184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04398290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Description: iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
Study NCT04398290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrogen gas
Description: 250 mcg/kg ideal body weight (IBW)/hour
Study NCT04398290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas
Description: Supplemental oxygen administered via nasal cannula
Study NCT04398290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Supplemental oxygen administered via nasal cannula
Study NCT02929329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil
Description: Omecamtiv mecarbil tablets for oral administration
Study NCT02929329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT02929329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
Study NCT02929329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
Study NCT02885324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Subjects will receive Cabozantinib
Study NCT00473265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH
Study NCT01769768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
Study NCT01769768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafarin
Description: 15 mg single dose of warfarin (oral tablet) will be given to patients.
Study NCT01769768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
Study NCT01470001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: solifenacin
Description: patient will receive solifenacin 5mg daily or placebo daily
Study NCT01470001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: patient will receive solifenacin 5mg daily or placebo daily
Study NCT04688619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Program young In Favor of Myself, active parents
Description: Prevention program: young In Favor of Myself, with parent participation
Study NCT04688619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention Program young In Favor of Myself, no parental involvement
Description: Prevention program: young In Favor of Myself, without parent participation
Study NCT04254822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Description: The TIPS procedures will be performed by experienced interventional radiologists. polytetrafluroethylene-covered stents were used with initial balloon dilatation to 8 mm, aiming for a decrease in portal-venous pressure gradient to less than 12 mm Hg.
Study NCT04254822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.
Study NCT04254822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.
Study NCT04254822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: For endoscopic variceal ligation, the first elective session will be carried out within 7 days of randomisation. Then EBL sessions were scheduled every 10-14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device).
Study NCT02530164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: active/sham tDCS as adjunctive treatment with a SSRI
Study NCT02530164 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: active/sham tDCS as adjunctive treatment with a SSRI
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial thickness at coordination scan
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at HCG
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at TVOR
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at ET
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial volume at coordination scan
Description: Ultrasound scan
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at HCG
Description: Blood test
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at TVOR
Description: Blood test
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at ET
Description: Blood test
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for progesterone at coordination scan
Description: Blood test
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Change in endometrial pattern between TVOR and ET
Description: Ultrasound scan
Study NCT04606771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib + Savolitinib
Description: Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD
Study NCT04606771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib + Placebo
Description: Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD
Study NCT03497416 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01698190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound guided needle tissue acquisition.
Description: Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at HCG
Description: Blood test
Study NCT03860636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test for estradiol at TVOR
Description: Blood test
Study NCT04357600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Umbilical Cord Mesenchymal Stem Cell
Description: All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the degree of liver function damage consisting of an examination of liver function, Child-Pugh score, and MELD score.
Study NCT02797275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Beta agonist respiratory inhaler
Study NCT02797275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: respiratory inhaler with no medication
Study NCT00253084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 200 mg
Description: IPX054 containing 50 mg carbidopa and 200 mg levodopa
Study NCT00253084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
Study NCT00253084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX054 Placebo
Description: Placebo to match IPX054 200 mg
Study NCT00253084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CD-LD IR Placebo
Description: Placebo to match CD-LD IR
Study NCT01062802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg, once a day for four weeks.
Study NCT01062802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given once daily for 4 weeks.
Study NCT02892695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK cells
Description: The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
Study NCT03096080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: One dose of the study drug in liquid form
Study NCT02435121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR125844
Description: Pharmaceutical form:Concentrate for solution Route of administration: intravenous
Study NCT04059627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Track
Description: Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd.
Study NCT01253304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Subcutaneous (SC) injection
Study NCT01327495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo acyline
Description: Placebo acyline subcutaneous injection every 2 weeks
Study NCT01327495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: daily placebo testosterone gel applied transdermally x 12 weeks
Study NCT01327495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 1% gel 1.25 g
Description: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Study NCT01327495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 1% gel 2.5 g
Description: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Study NCT01327495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 1% gel 5.0 g
Description: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Study NCT01327495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone 1% gel 10 g
Description: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Study NCT01327495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone 1% gel 15 g
Description: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Study NCT01327495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: 300 ug/kg subcutaneous injection every 2 weeks
Study NCT02051959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal stimulation of M1 + sham
Description: 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
Study NCT02051959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham + Anodal stimulation of M1
Description: 8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
Study NCT02051959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal stimulation of M1 + sham
Description: 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
Study NCT02051959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham + Cathodal stimulation of M1
Description: 8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
Study NCT02757040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib combined with As2O3
Description: arsenic trioxide combined with ibrutinib in CLL
Study NCT02757040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibrutinib
Description: ibrutinib
Study NCT01189175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823 + Ketokonazole
Description: 5 days ketokonazole with single oral dose of BI 113823 on day 3
Study NCT01189175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823
Description: single oral dose
Study NCT01503385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
Study NCT00958503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamphenicol
Description: 750 and 1500 mg/day;tablets
Study NCT00958503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets without active ingredient
Study NCT01854138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Incision Management System
Description: Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
Study NCT01353859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks for a total of 6 infusions
Study NCT01353859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25 mg orally weekly
Study NCT05625451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic Tension Digital Neoprene Orthosis
Description: The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.
Study NCT05625451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic Tension Digital Neoprene Orthosis
Description: The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.
Study NCT00720772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% intravenous (IV) sodium thiosulfate
Description: 50 ml IV drip twice/week post hemodialysis
Study NCT04266600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive mesentery resection
Description: Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis
Study NCT04134988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medimoov
Description: The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.
Study NCT04134988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychomotor therapy
Description: Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
Study NCT01744938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative biliary drainage
Description: percutaneous preoperative biliary drainage guided by CT
Study NCT02083120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHF therapy
Description: AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
Study NCT02083120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long term Oxygen Therapy (LOT)
Description: Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.